These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31648477)

  • 21. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
    Gill S; Vides V; Frey NV; Hexner EO; Metzger S; O'Brien M; Hwang WT; Brogdon JL; Davis MM; Fraietta JA; Gaymon AL; Gladney WL; Lacey SF; Lamontagne A; Mato AR; Maus MV; Melenhorst JJ; Pequignot E; Ruella M; Shestov M; Byrd JC; Schuster SJ; Siegel DL; Levine BL; June CH; Porter DL
    Blood Adv; 2022 Nov; 6(21):5774-5785. PubMed ID: 35349631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
    Burke JM
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):427-435. PubMed ID: 35577753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
    Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
    Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
    Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
    Ito Y; Makita S; Maeshima AM; Hatta S; Suzuki T; Yuda S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Intern Med; 2018 Aug; 57(16):2395-2398. PubMed ID: 29526963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
    Mato AR; Tang B; Azmi S; Yang K; Zhang X; Stern JC; Hedrick E; Huang J; Sharman JP
    Haematologica; 2022 Nov; 107(11):2630-2640. PubMed ID: 35443563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.
    Cadot S; Audebert C; Dion C; Ken S; Dupré L; Largeaud L; Laurent C; Ysebaert L; Crauste F; Quillet-Mary A
    PLoS Med; 2024 Jul; 21(7):e1004430. PubMed ID: 39037964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
    Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    Hampel PJ; Rabe KG; Call TG; Ding W; Leis JF; Kenderian SS; Muchtar E; Wang Y; Koehler AB; Parrondo R; Schwager SM; Shi M; Braggio E; Slager SL; Kay NE; Parikh SA
    Br J Haematol; 2022 Oct; 199(2):239-244. PubMed ID: 35841338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
    Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W; Heerema NA; Johnson AJ; Luan Y; James DF; Chu AD; Byrd JC
    Blood; 2018 Apr; 131(17):1910-1919. PubMed ID: 29437592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
    Scarfò L; Heltai S; Albi E; Scarano E; Schiattone L; Farina L; Moia R; Deodato M; Ferrario A; Motta M; Reda G; Sancetta R; Coscia M; Rivela P; Laurenti L; Varettoni M; Perotta E; Capasso A; Ranghetti P; Colia M; Ghia P
    Blood; 2022 Dec; 140(22):2348-2357. PubMed ID: 35921541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
    Deeks ED
    Drugs; 2017 Feb; 77(2):225-236. PubMed ID: 28105602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.